Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGCG | Q16739 | 8/20 | 0.35 |
| ▸ | CETP | P11597 | 6/20 | 0.34 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
| ▸ | ACACB | O00763 | 1/20 | 0.32 |
| ▸ | ACACA | Q13085 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5751760 | 0.98 | UGCG (0.36) | UGCGCETPSMN1; SMN2LMNABACE1 | |
| SCHEMBL5750844 | 0.96 | CETP (0.34) | UGCGCETPLMNABACE1SCN9A | |
| SCHEMBL5753971 | 0.94 | CETP (0.36) | UGCGCETPBACE1SCN9A | |
| SCHEMBL5750212 | 0.92 | CETP (0.34) | UGCGCETPBACE1SCN9A | |
| SCHEMBL5753310 | 0.92 | CETP (0.34) | UGCGCETPBACE1SCN9A | |
| SCHEMBL5753982 | 0.92 | UGCG (0.39) | UGCGCETPLMNABACE1 | |
| SCHEMBL5752710 | 0.91 | HCRTR1 (0.35) | UGCGCETP | |
| SCHEMBL5751982 | 0.91 | UGCG (0.33) | UGCGCETPBACE1 | |
| SCHEMBL5752295 | 0.91 | CETP (0.32) | UGCGCETPBACE1SCN9A | |
| SCHEMBL5752421 | 0.91 | CETP (0.39) | UGCGCETPBACE1ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6982348-B2 | Aminoethanol derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-01-03 | — | — | US | disclosed |
| US-20040127574-A1 | Aminoethanol derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127574-A1 | Aminoethanol derivatives | CETP, LCAT, MTTP | UGCG 740/4885CETP 1/4885ADRB3 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.